Cargando…
Clinical experience of cefiderocol
Infections by antibiotic-resistant microorganisms could be considered a “stealth pandemic” that we fight daily in most hospitals. Some estimates suggest that today 700,000 deaths per year can be attributed to antimicrobial resistance. By the year 2050, it is estimated that this will increase to ten...
Autor principal: | Fariñas, María Carmen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedad Española de Quimioterapia
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632058/ https://www.ncbi.nlm.nih.gov/pubmed/36193983 http://dx.doi.org/10.37201/req/s02.05.2022 |
Ejemplares similares
-
The role of cefiderocol in clinical practice
por: Maseda, Emilio, et al.
Publicado: (2022) -
Mechanism of action of cefiderocol
por: Soriano, Alex, et al.
Publicado: (2022) -
Antibacterial spectrum of cefiderocol
por: Cordero, Desirée Gijón, et al.
Publicado: (2022) -
Pharmacokinetics/Pharmacodynamics and tolerability of cefiderocol in the clinical setting
por: Perea, José Ramón Azanza, et al.
Publicado: (2022) -
Resistance to beta-lactams in Gram-negative bacilli: relevance and potential therapeutic alternatives
por: Garcia-Bustos, Víctor, et al.
Publicado: (2022)